MCID: PRK057
MIFTS: 78

Parkinson Disease, Late-Onset

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Mental diseases, Metabolic diseases

Aliases & Classifications for Parkinson Disease, Late-Onset

MalaCards integrated aliases for Parkinson Disease, Late-Onset:

Name: Parkinson Disease, Late-Onset 53 28 37 69
Parkinson Disease 53 12 23 49 24 71 28 51 41 69
Parkinson's Disease 37 12 72 49 24 50 36 40 14
Late Onset Parkinson Disease 12 71 14
Primary Parkinsonism 49 24 71
Paralysis Agitans 12 49 71
Pd 53 24 71
Parkinson Disease, Late-Onset, Susceptibility to 53 13
Park 53 71
Parkinson Disease, Age of Onset, Modifier 53
Parkinson Disease, Susceptibility to 53
Idiopathic Parkinson Disease 71
Lewy Body Parkinson Disease 71
Shaking Palsy 49
Parkinson's 59

Characteristics:

OMIM:

53
Inheritance:
isolated cases
multifactorial

Miscellaneous:
progressive disorder
insidious onset
onset mid to late adulthood
levodopa-responsive


HPO:

31
parkinson disease, late-onset:
Onset and clinical course insidious onset progressive
Inheritance sporadic


Classifications:



Summaries for Parkinson Disease, Late-Onset

NIH Rare Diseases : 49 Parkinson disease (PD) is a neurologic disease that affects the movement. The four main symptoms are tremors of the hands, arms, legs, jaw, or head, specially at rest; rigidity, or stiffness; bradykinesia, or slow movement; and postural instability or inability to find balance. The symptoms start slowly, but progress over time, impairing  everyday activities such as walking, talking, or completing simple tasks. Other symptoms may include emotional problems, trouble swallowing and speaking; urinary problems or constipation; skin problems; sleep problems, low blood pressure when standing up from sitting or lying down (postural hypotension), and inexpressive face. Some people will loose their mental abilities (dementia).   Parkinson disease affects several regions of the brain, especially a region known as "substantia nigra" that helps controlling balance and movement. Most cases of PD are sporadic (with no family history), and with onset around 60 years of age; onset before age 20 years is considered to be juvenile-onset Parkinson disease, and after age 50 years is considered late-onset Parkinson disease. However, in some families, there are several cases of Parkinson disease. Familial cases of Parkinson disease, and maybe some sporadic cases, can be caused by changes (mutations) in several genes, such as: Mutations in the SNCA (PARK1), LRRK2 (PARK8), and VPS35 (PARK17) genes are inherited in an autosomal dominant manner. Mutations in genes PARK2, PARK7, and PINK1 (PARK6) appear to be inherited in a recessive manner. Very rare mutations in the TAF1 gene cause Parkinson disease with X-linked inheritance. Mutations in some genes, including GBA and UCHL1 (PARK 5), do not seem to cause Parkinson disease, but to increase the risk of developing the disease in some families. Autosomal recessive PD have earlier onset than autosomal dominant PD. Some studies suggest that these genes are also involved in early-onset or juvenile PD. However, inheriting a mutation does not always mean that a person will have Parkinson's disease, because there may be other genes and environmental factors determining who will develop Parkinson disease. Treatment is usually based on a medication known as levodopa. Other medication includes bromocriptine, pramipexole, ropinirole, amantadine, rasagiline and safinamide.  Deep brain stimulation (DBS) a surgical procedure where electrodes are implanted into the brain may be useful for some people.Prognosis varies, and while some people become disabled, others will have only minor movement problems. Studies have shown that people with PD who have cognitive impairment, postural hypotension, and sleep problems may have a more rapid progression of the disease. Last updated: 11/16/2017

MalaCards based summary : Parkinson Disease, Late-Onset, also known as parkinson disease, is related to parkinson disease 2, autosomal recessive juvenile and hereditary late-onset parkinson disease, and has symptoms including constipation, dystonia and bradykinesia. An important gene associated with Parkinson Disease, Late-Onset is GLUD2 (Glutamate Dehydrogenase 2), and among its related pathways/superpathways are Parkinson's disease and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Rasagiline and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include Brain and Brain, and related phenotypes are behavior/neurological and homeostasis/metabolism

OMIM : 53 Parkinson disease was first described by James Parkinson in 1817. It is the second most common neurodegenerative disorder after Alzheimer disease (AD; 104300), affecting approximately 1% of the population over age 50 (Polymeropoulos et al., 1996). (168600)

UniProtKB/Swiss-Prot : 71 Parkinson disease: A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.

MedlinePlus : 40 Parkinson's disease (PD) is a type of movement disorder. It happens when nerve cells in the brain don't produce enough of a brain chemical called dopamine. Sometimes it is genetic, but most cases do not seem to run in families. Exposure to chemicals in the environment might play a role. Symptoms begin gradually, often on one side of the body. Later they affect both sides. They include Trembling of hands, arms, legs, jaw and face Stiffness of the arms, legs and trunk Slowness of movement Poor balance and coordination As symptoms get worse, people with the disease may have trouble walking, talking, or doing simple tasks. They may also have problems such as depression, sleep problems, or trouble chewing, swallowing, or speaking. There is no lab test for PD, so it can be difficult to diagnose. Doctors use a medical history and a neurological examination to diagnose it. PD usually begins around age 60, but it can start earlier. It is more common in men than in women. There is no cure for PD. A variety of medicines sometimes help symptoms dramatically. Surgery and deep brain stimulation (DBS) can help severe cases. With DBS, electrodes are surgically implanted in the brain. They send electrical pulses to stimulate the parts of the brain that control movement. NIH: National Institute of Neurological Disorders and Stroke

NINDS : 50 Parkinson's disease (PD) belongs to a group of conditions called motor system disorders, which are the result of the loss of dopamine-producing brain cells. The four primary symptoms of PD are tremor, or trembling in hands, arms, legs, jaw, and face; rigidity, or stiffness of the limbs and trunk; bradykinesia, or slowness of movement; and postural instability, or impaired balance and coordination. As these symptoms become more pronounced, patients may have difficulty walking, talking, or completing other simple tasks. PD usually affects people over the age of 60.  Early symptoms of PD are subtle and occur gradually.  In some people the disease progresses more quickly than in others.  As the disease progresses, the shaking, or tremor, which affects the majority of people with PD may begin to interfere with daily activities.  Other symptoms may include depression and other emotional changes; difficulty in swallowing, chewing, and speaking; urinary problems or constipation; skin problems; and sleep disruptions.  There are currently no blood or laboratory tests that have been proven to help in diagnosing sporadic PD.  Therefore the diagnosis is based on medical history and a neurological examination.  The disease can be difficult to diagnose accurately.   Doctors may sometimes request brain scans or laboratory tests in order to rule out other diseases.

Genetics Home Reference : 24 Parkinson disease is a progressive disorder of the nervous system. The disorder affects several regions of the brain, especially an area called the substantia nigra that controls balance and movement.

Disease Ontology : 12 A synucleinopathy that has material basis in degeneration of the central nervous system that often impairs motor skills, speech, and other functions.

PubMed Health : 59
About parkinson's: Parkinson's is a disease of the nervous system that mostly affects older people. It typically begins after the age of 50. The disease can be very hard to live with because it severely restricts mobility and as a result makes daily activities increasingly difficult. Parkinson's is a progressive disease, which means that in most cases it will continue to gradually get worse. Many people who develop Parkinson’s will require nursing care. There is no cure for the disease and its exact cause is not known, but there are effective treatments that can relieve the symptoms.

Wikipedia : 72 Parkinson\'s disease (PD) is a long-term degenerative disorder of the central nervous system that mainly... more...

GeneReviews: NBK1223

Related Diseases for Parkinson Disease, Late-Onset

Diseases in the Parkinson Disease, Late-Onset family:

Parkinson Disease 1, Autosomal Dominant Parkinson Disease 15, Autosomal Recessive Early-Onset
Parkinson Disease 12 Parkinson Disease 2, Autosomal Recessive Juvenile
Parkinson Disease 3, Autosomal Dominant Parkinson Disease 4, Autosomal Dominant
Parkinson Disease 6, Autosomal Recessive Early-Onset Parkinson Disease 7, Autosomal Recessive Early-Onset
Parkinson Disease 10 Parkinson Disease 8, Autosomal Dominant
Parkinson Disease 11, Autosomal Dominant Parkinson Disease 13, Autosomal Dominant
Parkinson Disease 14, Autosomal Recessive Parkinson Disease 16
Parkinson Disease 5, Autosomal Dominant Parkinson Disease 17
Parkinson Disease 18, Autosomal Dominant Parkinson Disease 19a, Juvenile-Onset
Parkinson Disease 20, Early-Onset Parkinson Disease 21
Parkinson Disease 22, Autosomal Dominant Parkinson Disease 23, Autosomal Recessive Early-Onset
Juvenile-Onset Parkinson Disease Early-Onset Parkinson Disease
Parkinson Disease Type 9 Hereditary Late-Onset Parkinson Disease

Diseases related to Parkinson Disease, Late-Onset via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 190)
# Related Disease Score Top Affiliating Genes
1 parkinson disease 2, autosomal recessive juvenile 35.2 LRRK2 PINK1 PRKN SNCA VPS13C
2 hereditary late-onset parkinson disease 34.7 GBA LRRK2 SNCA
3 parkinson disease 3, autosomal dominant 33.6 LRRK2 MAPT PRKN SNCA SNCAIP
4 multiple system atrophy 1 33.1 LRRK2 MAPT PRKN SNCA TH
5 corticobasal degeneration 32.9 GBA LRRK2 MAPT
6 dementia, lewy body 32.7 GBA LRRK2 MAPT PRKN SNCA SNCAIP
7 tremor 31.3 GBA LRRK2 MAPT PRKN SNCA
8 dementia 31.1 GBA MAPT PRKN SNCA SNCAIP
9 essential tremor 30.7 LRRK2 PRKN SNCA
10 restless legs syndrome 30.6 ATXN3 PRKN SNCA TH
11 parkes weber syndrome 12.5
12 paralysis agitans, juvenile, of hunt 12.2
13 glaucoma-related pigment dispersion syndrome 11.6
14 prolidase deficiency 11.6
15 parkinson disease 4, autosomal dominant 11.6
16 pendred syndrome 11.5
17 parkinson disease 1, autosomal dominant 11.3
18 klippel-trenaunay-weber syndrome 11.1
19 personality disorder 11.1
20 synucleinopathy 11.0 GBA LRRK2 MAPT NR4A2 PINK1 PRKN
21 ehlers-danlos syndrome, spondylodysplastic type, 1 11.0
22 spondylodysplastic ehlers-danlos syndrome 11.0
23 nervous system disease 11.0 ATXN3 LRRK2 MAPT PINK1 PRKN SNCA
24 parkinson disease 10 11.0 LRRK2 PARK10 PINK1 PRKN SNCA VPS13C
25 central nervous system disease 11.0 ATXN3 LRRK2 MAPT PINK1 PRKN SNCA
26 erythroleukemia, familial 11.0
27 movement disease 11.0 LRRK2 MAPT PINK1 PRKN SNCA TH
28 parkinson disease 14, autosomal recessive 11.0
29 early-onset parkinson disease 10.9 GBA LRRK2 PINK1 PRKN SNCA
30 parkinson disease type 9 10.9
31 parkinson disease 15, autosomal recessive early-onset 10.9 LRRK2 PINK1 PRKN SNCA TH
32 supranuclear palsy, progressive, 1 10.9 LRRK2 MAPT PRKN SNCA TH
33 parkinson disease 19a, juvenile-onset 10.9
34 aceruloplasminemia 10.9 ATXN2 ATXN3 SNCA TBP
35 pendred syndrome/nonsyndromic enlarged vestibular aqueduct 10.9
36 dysautonomia 10.9 PRKN SNCA SNCAIP
37 postencephalitic parkinson disease 10.9 LRRK2 MAPT SNCA
38 autosomal dominant cerebellar ataxia 10.8 ATXN2 ATXN3 SNCA TBP
39 neuronal intranuclear inclusion disease 10.8 ATXN3 MAPT SNCA
40 hereditary ataxia 10.8 ATXN2 ATXN3 TBP
41 thyroid dyshormonogenesis 1 10.8
42 thyroid dyshormonogenesis 2a 10.8
43 charcot-marie-tooth disease, x-linked recessive, 5 10.8
44 abdominal obesity-metabolic syndrome 1 10.8
45 osteofibrous dysplasia 10.8
46 capillary malformation-arteriovenous malformation 10.8
47 congenital disorder of glycosylation, type iin 10.8
48 myopathy, distal, 5 10.8
49 duane retraction syndrome 3 with or without deafness 10.8
50 spinocerebellar ataxia 12 10.8 ATXN2 ATXN3 TBP

Comorbidity relations with Parkinson Disease, Late-Onset via Phenotypic Disease Network (PDN): (show top 50) (show all 53)


Active Peptic Ulcer Disease Acute Conjunctivitis
Acute Cystitis Alzheimer Disease
Anxiety Atypical Depressive Disorder
Autonomic Nervous System Disease Bipolar Disorder
Blepharitis Bronchitis
Bronchopneumonia Cerebral Atherosclerosis
Cerebral Degeneration Cerebrovascular Disease
Chronic Myocardial Ischemia Communicating Hydrocephalus
Conjunctivitis Cystitis
Decubitus Ulcer Deficiency Anemia
Delusional Disorder Dependent Personality Disorder
Dysthymic Disorder Early-Onset Generalized Limb-Onset Dystonia
Encephalopathy Erythematosquamous Dermatosis
Esophagitis Fecal Incontinence
Generalized Atherosclerosis Heart Disease
Hypothyroidism Intestinal Volvulus
Iron Deficiency Anemia Leukodystrophy
Major Affective Disorder 9 Major Depressive Disorder
Marasmus Mood Disorder
Neurogenic Bladder Obstructive Hydrocephalus
Osteoporosis Paralytic Ileus
Paranoid Schizophrenia Pernicious Anemia
Personality Disorder Prostatic Hypertrophy
Protein-Energy Malnutrition Pseudobulbar Palsy
Schizophrenia Schizophreniform Disorder

Graphical network of the top 20 diseases related to Parkinson Disease, Late-Onset:



Diseases related to Parkinson Disease, Late-Onset

Symptoms & Phenotypes for Parkinson Disease, Late-Onset

Symptoms via clinical synopsis from OMIM:

53
Abdomen Gastroin testinal:
constipation
dysphagia

Neurologic Behavioral Psychiatric Manifestations:
depression

Head And Neck Face:
masked facies

Neurologic Central Nervous System:
sleep disturbances
dystonia
bradykinesia
dysarthria
rigidity
more
Genitourinary Bladder:
urinary urgency

Head And Neck Nose:
decreased sense of smell


Clinical features from OMIM:

168600

Human phenotypes related to Parkinson Disease, Late-Onset:

31 (show all 22)
# Description HPO Frequency HPO Source Accession
1 constipation 31 HP:0002019
2 dystonia 31 HP:0001332
3 bradykinesia 31 HP:0002067
4 personality changes 31 HP:0000751
5 dysarthria 31 HP:0001260
6 dysphagia 31 HP:0002015
7 sleep disturbance 31 HP:0002360
8 dysautonomia 31 occasional (7.5%) HP:0002459
9 hallucinations 31 occasional (7.5%) HP:0000738
10 mask-like facies 31 HP:0000298
11 rigidity 31 HP:0002063
12 dementia 31 HP:0000726
13 weak voice 31 HP:0001621
14 parkinsonism 31 HP:0001300
15 postural instability 31 HP:0002172
16 neuronal loss in central nervous system 31 HP:0002529
17 urinary urgency 31 HP:0000012
18 short stepped shuffling gait 31 HP:0007311
19 resting tremor 31 HP:0002322
20 lewy bodies 31 HP:0100315
21 depressivity 31 HP:0000716
22 substantia nigra gliosis 31 HP:0011960

UMLS symptoms related to Parkinson Disease, Late-Onset:


sleeplessness, equilibration disorder, vertigo/dizziness, chronic pain, tremor, syncope, seizures, sciatica, pain, myoclonus, headache, back pain, angina pectoris, constipation, muscle rigidity, sleep disturbances, urgency of micturition, bradykinesia, resting tremor, hyposmia

MGI Mouse Phenotypes related to Parkinson Disease, Late-Onset:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10 PRKN SNCA TBP TH ATXN2 ATXN3
2 homeostasis/metabolism MP:0005376 9.97 ADH1C ATXN2 ATXN3 GBA LRRK2 MAPT
3 nervous system MP:0003631 9.7 ATXN2 ATXN3 GBA LRRK2 MAPT NR4A2
4 no phenotypic analysis MP:0003012 9.17 LRRK2 MAPT PINK1 PRKN SNCA TBP

Drugs & Therapeutics for Parkinson Disease, Late-Onset

PubMedHealth treatment related to Parkinson Disease, Late-Onset: 59

Parkinson's is usually treated with medication. At the beginning of the disease – when the symptoms are not problematic – treatment is sometimes not necessary. If the symptoms get worse, medication can help. Treatment with medication generally aims to replace the lacking dopamine. That often relieves symptoms, but does not slow the progress of the disease. Because over time the drugs are no longer effective, the type and dose of medication has to be adjusted again and again. One option is to use a medication pump. It provides the drug either under the skin or directly into the small intestine and ensures a constant supply.Occupational therapy is used to practice everyday movements and activities. Restricted movement means that the muscles lose strength. Movement exercises (physiotherapy) and sports aim to help counteract that and improve movement and coordination. Speech therapy can be an option if the voice becomes quieter and speech less clear.Deep brain stimulation is recommended to some people whose symptoms are not relieved enough by taking medication. That involves surgery to implant electrodes in certain parts of the brain. They continuously emit electrical impulses that influence muscle activity.

Drugs for Parkinson Disease, Late-Onset (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 539)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rasagiline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 136236-51-6 3052776
2
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120014-06-4 3152
3
Nicotine Approved Phase 4,Phase 2,Phase 1,Not Applicable 54-11-5 89594 942
4
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
5
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
6
Pramipexole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 104632-26-0 119570 59868
7
Ropinirole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 91374-20-8, 91374-21-9 5095 497540
8
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-92-7 6047
9
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 123441-03-2 77991
10
Amantadine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 768-94-5 2130
11
Carbidopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28860-95-9 38101 34359
12
Entacapone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 130929-57-6 5281081
13 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
14
Apomorphine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 58-00-4, 41372-20-7 6005
15
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
16
Midodrine Approved Phase 4,Phase 1,Not Applicable 42794-76-3, 133163-28-7 4195
17
Armodafinil Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 112111-43-0
18
Modafinil Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 68693-11-8 4236
19
Zonisamide Approved, Investigational Phase 4,Phase 2,Phase 3 68291-97-4 5734
20
Iodine Approved, Investigational Phase 4,Phase 2 7553-56-2 807
21
Galantamine Approved Phase 4,Phase 2,Not Applicable 357-70-0 9651
22
Cabergoline Approved Phase 4,Phase 3,Not Applicable 81409-90-7 54746
23
Memantine Approved, Investigational Phase 4,Phase 2,Not Applicable 19982-08-2 4054
24
Lubiprostone Approved, Investigational Phase 4,Not Applicable 136790-76-6 656719
25
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2 16590-41-3 5360515
26
Selegiline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 14611-51-9 5195 26757
27
Bromocriptine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 25614-03-3 31101
28
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
29
Methylphenidate Approved, Investigational Phase 4,Phase 2,Early Phase 1,Not Applicable 20748-11-2, 113-45-1 4158
30
Norepinephrine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 51-41-2 439260
31
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 76631-46-4, 113775-47-6 5311068 56032 68602
32
Trimethobenzamide Approved, Investigational Phase 4,Phase 1 138-56-7 5577
33 Benserazide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 322-35-0
34
Atenolol Approved Phase 4 29122-68-7 2249
35
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
36
Trandolapril Approved Phase 4 87679-37-6 5484727
37
Verapamil Approved Phase 4 52-53-9 2520
38
Topiramate Approved Phase 4,Phase 2,Not Applicable 97240-79-4 5284627
39
Droxidopa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23651-95-8 443940
40 Mirabegron Approved Phase 4 223673-61-8
41
Fesoterodine Approved Phase 4 286930-02-7, 286930-03-8 6918558
42
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
43
Suvorexant Approved, Investigational Phase 4 1030377-33-3
44
Tetrabenazine Approved, Investigational Phase 4 58-46-8 6018
45
Varenicline Approved, Investigational Phase 4,Phase 2 249296-44-4 5310966
46
Amitriptyline Approved Phase 4 50-48-6 2160
47
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
48
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
49
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
50
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741

Interventional clinical trials:

(show top 50) (show all 2257)

# Name Status NCT ID Phase Drugs
1 A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients Unknown status NCT01007630 Phase 4 Rasagiline;Placebo
2 The Effect of Donepezil on Gait and Balance in Parkinson's Disease Unknown status NCT01521117 Phase 4 Donepezil
3 Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson's Disease Unknown status NCT00354133 Phase 4
4 Validation of DaTscan for Detection of Parkinson Disease Related Disorders Unknown status NCT02138682 Phase 4 l-123 Ioflupane
5 Nicotine Treatment of Impulsivity in Parkinson's Disease Unknown status NCT01216904 Phase 4 nicotine patch;placebo
6 Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study Unknown status NCT01765257 Phase 4 AZILECT®;Placebo
7 The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease Unknown status NCT00696215 Phase 4 placebo;rasagiline
8 Emotion, Mood and Executive Function in Parkinson`s Disease (PD) Unknown status NCT01385735 Phase 4 Rasagiline;Placebo
9 Effect of Deep Brain Stimulation on Gait of Patients With Parkinson's Disease Depending on Electrode Location in Subthalamic Area Unknown status NCT01782638 Phase 4
10 Botulinum A Toxin in Patients With Parkinson's Disease Unknown status NCT00822913 Phase 4 Intravesical injection of Botulinum A toxin
11 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4 Botulinum Toxin
12 Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID) Unknown status NCT01515774 Phase 4 Mirapex ER
13 Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients Unknown status NCT01780467 Phase 4
14 Cognitive Decline in Non-demented PD Unknown status NCT01340885 Phase 4 Strattera;Exelon
15 The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy Unknown status NCT01313819 Phase 4 PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj
16 Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa Unknown status NCT01683253 Phase 4 Levodopa/Carbidopa(200mg/50mg)
17 Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia Unknown status NCT00142259 Phase 4
18 Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy Completed NCT01782222 Phase 4 Rotigotine
19 Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease Completed NCT01723228 Phase 4 Rasagiline;Placebo
20 Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease Completed NCT01032486 Phase 4 Rasagiline mesylate
21 Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off Completed NCT00391898 Phase 4 Levodopa/carbidopa/entacapone;Levodopa/carbidopa
22 Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease Completed NCT00219284 Phase 4 Carbidopa/levodopa/entacapone
23 Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease Completed NCT01049984 Phase 4 Rasagiline;Placebo
24 Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease Completed NCT00914134 Phase 4 Levodopa infusion
25 Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients Completed NCT01523301 Phase 4 Rotigotine;Placebo
26 A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease Completed NCT01485172 Phase 4 ropinirole monotherapy;placebo monotherapy
27 Virtual Exercises in Patients With Parkinson's Disease. Completed NCT02023034 Phase 4
28 Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit Completed NCT00272688 Phase 4 Levodopa (drug), intraduodenal administration
29 Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD) Completed NCT00321854 Phase 4 pramipexole
30 Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease Completed NCT01168596 Phase 4 Rasagiline;Placebo
31 Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease Completed NCT00153972 Phase 4 Cabergoline;Levodopa
32 Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease Completed NCT00646204 Phase 4 Memantine;placebo
33 Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms Completed NCT01300819 Phase 4 Rotigotine
34 Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management Completed NCT03103919 Phase 4 Rotigotine
35 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain Completed NCT01744496 Phase 4 Rotigotine;Placebo
36 Amitiza in Constipation Associated With PD (Parkinson's Disease) Completed NCT00908076 Phase 4 LUBIPROSTONE
37 Rasagiline and Apathy in Parkinson's Disease Completed NCT00755027 Phase 4 Rasagiline
38 Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
39 Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States Completed NCT00143026 Phase 4 carbidopa, levodopa, entacapone
40 Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease Completed NCT01313845 Phase 4 amantadine sulfate;0.9% sodium chloride
41 Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease Completed NCT00640159 Phase 4 Zelapar
42 Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease Completed NCT01018264 Phase 4 solifenacin succinate (VESIcare);placebo
43 Mild Cognitive Impairment in Parkinson's Disease Completed NCT01519271 Phase 4 Exelon Patch (rivastigmine transdermal system);Placebo Patches
44 Olfaction in Patients With Parkinson's Disease Following Treatment With Rasagiline Completed NCT00902941 Phase 4 Azilect 1mg;Placebo
45 Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease Completed NCT02233023 Phase 4 Pramipexole;Bromocriptine and other dopamine agonists
46 Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists Completed NCT00443872 Phase 4 orally disintegrating selegiline (Zelapar)
47 A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy Completed NCT01497652 Phase 4 Rasagiline/Placebo;Rasagiline
48 Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment Completed NCT00651183 Phase 4 Pramipexole immediate release
49 A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease Completed NCT01494532 Phase 4 ropinirole/L-dopa;placebo/L-dopa
50 Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological, Pharmacokinetic and Genetic Profiles Completed NCT01733199 Phase 4

Search NIH Clinical Center for Parkinson Disease, Late-Onset

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Parkinson Disease, Late-Onset cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: parkinson disease

Genetic Tests for Parkinson Disease, Late-Onset

Genetic tests related to Parkinson Disease, Late-Onset:

# Genetic test Affiliating Genes
1 Parkinson Disease 28
2 Parkinson Disease, Late-Onset 28 ADH1C ATXN2 GBA GLUD2 MAPT NR4A2 SNCAIP TBP

Anatomical Context for Parkinson Disease, Late-Onset

MalaCards organs/tissues related to Parkinson Disease, Late-Onset:

38
Brain, Skin, Testes, Bone
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Parkinson Disease, Late-Onset:
# Tissue Anatomical CompartmentCell Relevance
1 Brain Substantia Nigra pars Compacta Adult Dopaminergic Neurons Potential therapeutic candidate, affected by disease
2 Brain Forebrain White Matter Fibrous Astrocyte Cells Potential therapeutic candidate
3 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
4 Brain Neocortex Protoplasmic Astrocyte Cells Potential therapeutic candidate
5 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Parkinson Disease, Late-Onset

Articles related to Parkinson Disease, Late-Onset:

(show top 50) (show all 769)
# Title Authors Year
1
Teaching Video NeuroImages: Oculogyric crisis in treated Parkinson disease. ( 29335315 )
2018
2
Behavioral addictions in early-onset Parkinson disease are associated with DRD3 variants. ( 29361389 )
2018
3
Prelemniscal Lesion for Selective Improvement of Parkinson Disease Tremor. ( 29408817 )
2018
4
Microstructural changes in patients with Parkinson disease and REM sleep behavior disorder: depressive symptoms versus non-depressed. ( 29442234 )
2018
5
The heterozygous R1441C mutation of leucine-rich repeat kinase 2 gene in a Chinese patient with Parkinson disease: A five-year follow-up and literatures review. ( 28131193 )
2017
6
Involvement of Gaucher Disease Mutations in Parkinson Disease. ( 26965692 )
2017
7
Dopa-responsive dystonia or early-onset Parkinson disease - Genotype-phenotype correlation. ( 27667361 )
2017
8
Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative ataxia group, and tremor research group. ( 28887904 )
2017
9
I+-Synuclein in the colon and premotor markers of Parkinson disease in neurologically normal subjects. ( 27803984 )
2017
10
Essential tremor & Parkinson disease: Recognizing the differences. ( 28926496 )
2017
11
REM sleep behavior disorder is related to enteric neuropathology in Parkinson disease. ( 28887374 )
2017
12
Downward finger displacement distinguishes Parkinson disease dementia from Alzheimer disease. ( 28911255 )
2017
13
Nonmotor Symptoms in Parkinson Disease: A Descriptive Review on Social Cognition Ability. ( 28073327 )
2017
14
Animal models of I+-synucleinopathy for Parkinson disease drug development. ( 28747776 )
2017
15
Genetic analysis of the TMEM230 gene in Chinese patients with familial Parkinson disease. ( 28038866 )
2017
16
Managing neurogenic orthostatic hypotension in a patient presenting with pure autonomic failure who later developed Parkinson disease. ( 28699048 )
2017
17
Differential Diagnosis of Parkinson Disease, Essential Tremor, and Enhanced Physiological Tremor with the Tremor Analysis of EMG. ( 28884038 )
2017
18
Pooled analysis of the HLA-DRB1 by smoking interaction in Parkinson disease. ( 28981958 )
2017
19
I+-Synucleinopathy in the Human Amygdala in Parkinson Disease: Differential Vulnerability of Somatostatin- and Parvalbumin-Expressing Neurons. ( 28859333 )
2017
20
The mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease. ( 28257421 )
2017
21
Restless legs syndrome in Parkinson disease: Clinical characteristics, abnormal iron metabolism and altered neurotransmitters. ( 28874701 )
2017
22
STN DBS for Advanced Parkinson Disease Simultaneously Alleviates Cluster Headache. ( 29422851 )
2017
23
Functional properties of LRRK2 mutations in Taiwanese Parkinson disease. ( 27423549 )
2017
24
Loss of phosphodiesterase 4 in Parkinson disease: Relevance to cognitive deficits. ( 28701494 )
2017
25
Prospective clinical and DaT-SPECT imaging in premotor LRRK2 G2019S-associated Parkinson disease. ( 28679601 )
2017
26
VCP-related multisystem proteinopathy presenting as early-onset Parkinson disease. ( 28724584 )
2017
27
Analysis of blood-based gene expression in idiopathic Parkinson disease. ( 28916538 )
2017
28
Is pure autonomic failure an early marker for Parkinson disease, dementia with Lewy bodies, and multiple system atrophy? And other updates on recent autonomic research. ( 28255741 )
2017
29
A Multicenter Comparative Study of Impulse Control Disorder in Latin American Patients With Parkinson Disease. ( 28288482 )
2017
30
microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease. ( 26911687 )
2016
31
Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy. ( 27958390 )
2016
32
Excessive Iron and I+-Synuclein Oligomer in Brain are Relevant to Pure Apathy in Parkinson Disease. ( 26940028 )
2016
33
Parkinson disease. Sleep disorder deficits suggest signature for early Parkinson disease. ( 26635212 )
2016
34
Orthostatic hypotension predicts motor decline in early Parkinson disease. ( 27639815 )
2016
35
Randomized controlled trials for Alzheimer disease and Parkinson disease. ( 27100346 )
2016
36
I+-synuclein genetic variability: A biomarker for dementia in Parkinson disease. ( 27091628 )
2016
37
Skin nerve misfolded I+-synuclein in pure autonomic failure and Parkinson disease. ( 26606657 )
2016
38
NFE2L2 variations reduce antioxidant response in patients with Parkinson disease. ( 26887053 )
2016
39
Impulsive-compulsive behaviors in parkin-associated Parkinson disease. ( 27590295 )
2016
40
The relationship between glucocerebrosidase mutations and Parkinson disease. ( 26860875 )
2016
41
Investigation of Genetic Variants Associated with Alzheimer Disease in Parkinson Disease Cognition. ( 26889634 )
2016
42
Assessment of Oropharyngeal Dysphagia in Patients With Parkinson Disease: Use of Ultrasonography. ( 27152267 )
2016
43
Increased copper toxicity in Saccharomyces cerevisiae lacking VPS35, a component of the retromer and monogenic Parkinson disease gene in humans. ( 27262440 )
2016
44
Pathological I+-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. ( 27015771 )
2016
45
Parkinson disease: New evidence for a pathogenic link between rosacea and Parkinson disease. ( 27063106 )
2016
46
The role of the melanoma gene MC1R in Parkinson disease and REM sleep behavior disorder. ( 27131830 )
2016
47
The Evolution of REM Sleep Behavior Disorder in Early Parkinson Disease. ( 27306265 )
2016
48
Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease. ( 27568909 )
2016
49
High-resolution arrays reveal burden of copy number variations on Parkinson disease genes associated with increased disease risk in random cohorts. ( 27399248 )
2016
50
Investigation of Motor Cortical Plasticity and Corticospinal Tract Diffusion Tensor Imaging in Patients with Parkinsons Disease and Essential Tremor. ( 27603204 )
2016

Variations for Parkinson Disease, Late-Onset

UniProtKB/Swiss-Prot genetic disease variations for Parkinson Disease, Late-Onset:

71
# Symbol AA change Variation ID SNP ID
1 PRKN p.Cys253Tyr VAR_019749 rs747427602
2 PRKN p.Arg256Cys VAR_019750 rs150562946
3 PRKN p.Arg275Trp VAR_019752 rs34424986
4 PRKN p.Asp280Asn VAR_019753 rs72480422

ClinVar genetic disease variations for Parkinson Disease, Late-Onset:

6 (show all 17)
# Gene Variation Type Significance SNP ID Assembly Location
1 TBP NM_003194.4(TBP): c.172_174CAG(25_42) (p.Gln95(25_42)) NT expansion Pathogenic,risk factor rs193922935 GRCh37 Chromosome 6, 170870996: 170870998
2 MT-ND1 m.3397A> G single nucleotide variant Pathogenic rs199476120 GRCh37 Chromoso